prasad_raju_land

Raju Prasad

Analyst
+1 312 364 8469
Email vCard

Specialties:  Biotechnology

Raju Prasad, Ph.D., a biotechnology analyst focused on therapeutics, joined William Blair in March 2014. Dr. Prasad previously worked as a research associate with the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. Dr. Prasad has a B.A. in cell biology and neuroscience from Rutgers University, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus in genetic toxicology and mutagenesis.

LogicBio Therapeutics, Inc.: Initiation of Research Coverage

William Blair initiated research coverage of LogicBio Therapeutics, Inc., a biotechnology company focused on developing medicines to treat rare genetic diseases using its proprietary GeneRide genome-editing technology. Learn More

Celyad S.A.: Initiation of Research Coverage

William Blair initiated research coverage of Celyad S.A., a clinical-stage biopharmaceutical company focused on the development of both autologous and allogeneic cell-based therapies to treat solid and hematologic tumors. Learn More

Initiation of Research Coverage of Two Gene Therapy Companies

William Blair & Company initiated research coverage of two gene therapy companies—Krystal Biotech, Inc. (KRYS $15.07) and Rocket Pharmaceuticals, Inc. (RCKT $19.17). Learn More